Based on the current data, in the set of patients with cirrhosis, having the highest risk of HCC, the performance of APAR in differentiating HCC patients from cirrhosis patients is not better than AFP (see Supplementary Fig. S1). This evidence concerns the gene AFP and hepatocellular carcinoma.